



Innovation Marketplace

SNAPSHOT

The Company

Founded in 2006, Ablitech, Inc. is a Hattiesburg, Mississippi-based company that draws from the latest advances in polymer science, molecular biology and medicinal chemistry. Ablitech develops platform RNAi delivery systems

The Technology

Versadel™ is a polymer based platform that delivers nucleic acid gene therapies for the treatment of all forms of cancer and other life threatening diseases.

The Opportunity

Thousands of labs around the world have developed gene therapeutics for curing cancer and virtually every other disease. These potential cures have failed to develop into commercial products because of failure delivering the genetic material, RNAi, antisense DNA, past the body's natural defense system and through the targeted cells membrane. Versadel™ promises to enable all of these treatments, unlocking multi-billion dollar markets.

The Opportunity

Ablitech is seeking \$15 million in venture funding.

ABLITECH, INC.

Ablitech, Inc. is a biotechnology company specializing in delivering gene therapeutics with the potential to stop cancer and most degenerative diseases.

Ablitech's flagship product, Versadel™, is a mechanism that provides a non-toxic, biocompatible method for the systemic and local delivery of antisense DNA and siRNA in the body. This therapeutic platform has the potential to treat a number of diseases and enable the multi-billion dollar RNAi therapeutics market.

Initial laboratory trials under a Phase I, SBIR, verify that Ablitech's product is adept at stopping affected cells from growing: eliminating their power to spread.

"The proof is in the lab," Malone says. "To date, Versadel™ has shown great advances in pancreatic, bladder and brain cancer."

Founded in 2006, Ablitech spun out of a National Science Foundation backed program to foster entrepreneurship uniting Dr. Nick Hammond of The University of Mississippi's Medicinal Chemistry Department and Dr. Lisa Kemp of The University of Southern Mississippi's School of Polymers and High Performance Materials.

In 2007, Ablitech received NSF SBIR Phase I funding, providing not only the initial funding for the development of its radical platform technology, but also a peer reviewed validation of the merit of the technology. This past September, Ablitech completed a \$700,000 seed capital round. All funds were raised from within Mississippi.

Next on the company's agenda: "Testing Versadel™ in animal models." Malone says, "Where we will see our theories in action."

Ablitech is seeking \$15 million in venture funding to be used to complete animal trials, develop strategic license partnerships and position the company for liquidity through licensing of the technology.

Contact:

Ken Malone, CEO

Hattiesburg, MS

601-266-8010

ken.malone@ablitech.com

